Monophosphoryl lipid A and QS21 increase CD8 T lymphocyte cytotoxicity to herpes simplex virus-2 infected cell proteins 4 and 27 through IFN-γ and IL-12 production

Journal of Immunology

Volumn 164, Issue 10, 2000, Pages 5167-5176

  Mikloska, Zorka ^a   Rückholdt, Monica ^a   Ghadiminejad, Iraj ^b   Dunckley, Heather ^c   Denis, Martine ^d   Cunningham, Anthony L ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; GAMMA INTERFERON; IMMEDIATE EARLY PROTEIN; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEUTRALIZING ANTIBODY; PHOSPHORYL LIPID A; QS 21;

ANTIGEN PRESENTATION; ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EPIDERMIS CELL; HERPES SIMPLEX; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINIA VIRUS;

EID: 0343527202     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.10.5167     Document Type: Article

References (37)

1. Schmid, D. S., and B. T. Rouse. 1992. The role of T cell immunity in control of herpes simplex virus. Curr. Top. Microbiol. Immunol. 179:57.
2. Mikloska, Z., V. A. Danis, S. Adams, A. R. Lloyd, D. L. Adrian, and A. L. Cunningham. 1998. In vivo production of cytokines and β (C-C) chemokines in human recurrent herpes simplex virus lesions: do herpes simplex virus infected keratinocytes contribute to their production? J. Infect. Dis. 177:827.
3. Mikloska, Z., P. P. Sanna, and A. L. Cunningham. 1999. Neutralising antibodies inhibit the axonal spread of HSV-1 to epidermal cells in vitro. J. Virol. 73:5934.
4. Cunningham, A. L., R. R. Turner, A. C. Miller, M. F. Para, and T. C. Merigan. 1985. Evolution of recurrent herpes simplex virus lesions. J. Clin. Invest. 75:226.
5. Hill, A., P. Jugovic, I. York, G. Russ, J. Bennink, J. Yewdell, H. Ploegh, and D. Johnson. 1995. Herpes simplex virus turns off TAP to evade host immunity. Nature 375:411.
6. Hill, A. B. 1996. Mechanisms of interference with the class I restricted pathway of antigen presentation by herpesviruses. Immunol. Cell Biol. 74:523.
7. Koelle, D. M., M. A. Tigges, R. L. Burke, F. W. Symington, S. R. Riddell, H. Abbo, and L. Corey. 1993. Herpes simplex virus infection of human fibroblasts and keratinocytes inhibits recognition by cloned CD8 cytotoxic T lymphocytes. J. Clin. Invest. 91:961.
8. Mikloska, Z., A. M. Kesson, M. E. T. Penfold, and A. L. Cunningham. 1996. Herpes simplex virus protein targets for CD4 and CD8 lymphocyte cytotoxicity in cultured epidermal keratinocytes treated with IFN-γ. J. Infect. Dis. 173:7.
9. Cunningham, A. L., and T. C. Merigan. 1983. γ-Interferon production appears to predict time of recurrence of herpes labialis. J. Immunol. 130:2397.
10. Torseth, J. W., and T. C. Merigan. 1986. Significance of local γ interferon in recurrent herpes simplex infection. J. Infect. Dis. 153:979.
11. + T-cells produce γ-interferon in patients with recurrent herpes labialis. J. Immunol. 132:197.
12. Milligan, G. N., D. I. Bernstein, and N. Bourne. 1998. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J. Immunol. 160:6093.
13. Milligan, G. N., and D. I. Bernstein. 1997. Interferon-γ enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology 229: 259.
14. Cunningham, A. L, and J. R. Noble. 1989. Role of keratinocytes in human recurrent herpetic lesions: ability to present herpes simplex virus antigen and act as targets for T lymphocyte cytotoxicity in vitro. J. Clin. Invest. 83:490.
15. Mikloska, Z., and A. L. Cunningham. 1998. Herpes simplex virus type 1 glycoproteins gB, gC and gD are major targets for CD4 T-lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes. J. Gen. Virol. 79:353.
16. Koelle, D. M., L. Corey, R. L. Burke, R. J. Eisenberg, G. H. Cohen, R. Pichyangkura, and S. J. Triezenberg. 1994. Antigenic specificities of human CD4 T cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. J. Virol. 68:2803.
17. Posavad, C. M., D. M. Koelle, and L. Corey. 1996. High frequency of CD8 cytotoxic T lymphocyte precursors specific for herpes simplex viruses in persons with genital herpes. J. Virol. 170:8165.
18. Koelle, D. M., J. M. Frank, M. L. Johnson, and W. W. Kwok. 1998. Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions. J. Virol. 72:7476.
19. Koelle, D. M., C. M. Posavad, G. R. Barnum, M. L. Johnson, J. M. Frank, and L. Corey. 1998. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J. Clin. Invest. 101: 1500.
20. Bonneau, R. H., and S. R. Jennings. 1989. Modulation of acute and latent herpes simplex virus infections in C57BL/6 mice by adoptive transfer of immune lymphocytes with cytolytic activity. J. Virol. 63:1480.
21. Banks, T. A., E. M. Allen, S. Dasgupta, R. Sandri-Goldin, and B. T. Rouse. 1991. Herpes simplex virus type 1-specific cytotoxic T lymphocytes recognize immediate early protein ICP27. J. Virol. 65:3185.
22. Martin, S., X. Zhu, S. J. Silverstein, R. J. Courtney, F. Yao, F. J. Jenkins, and B. T. Rouse. 1990. Murine cytotoxic T lymphocytes specific for herpes simplex virus type 1 recognize the immediate early protein ICP4 but not ICP0. J. Gen. Virol. 71:2391.
23. Brynestad, K., B. Babbit, L. Huang, and B. Rouse. 1990. Influence of peptide acylation, liposome incorporation and synthetic immunomodulators on the immunogenicity of a 1-23 peptide of glycoprotein D of herpes simplex virus: implications for subunit vaccines. J. Virol. 64:680.
24. Jones, G. J., P. von Hoegen, J. Weber, and A. D Rees. 1999. Immunization with human immunodeficiency virus type 1 rgp120W61D in QS21/MPL adjuvant primes T cell proliferation and C-C chemokine production to multiple epitopes within variable and conserved domains of gp120W61D. J. Infect. Dis. 179:558.
25. Keefer, M. C., M. Wolff, G. J. Gorse, B. S. Graham, L. Corey, M. L. Clements-Mann, N. Verani-Ketter, S. Erb, C. M. Smith, R. B. Belshe, et al. 1997. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses 13:1163.
26. Katayama S., K. Oda, T. Ohgitani, T. Hirakara, and Y. Shimizu. 1999. Influence of antigenic forms and adjuvants on the IgG subclass antibody response to Aujeszky's disease virus in mice. Vaccine 17:2733.
27. Moore, A., L. McCarthy, and K. H. Mills. 1999. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine 17:2517.
28. + T cells. J. Virol. 69:4711.
29. Jurewicz, A., W. E. Biddison, and J. P. Antel. 1998. MHC class 1-restricted lysis of human olygodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytes. J. Immunol. 160:3056.
30. + CTL responses in vitro. J. Clin. Invest. 98:715.
31. Kalams, S. A., and B. D. Walker. 1998. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte response. J. Exp. Med. 188:2199.
32. Tomazin, R., N. E. van Schoot, K. Goldsmith, P. Jugovic, P. Sempe, K. Fruh, and D. C. Johnson. 1998. Herpes simplex virus type 2 ICP47 inhibits human TAP but not mouse TAP. J. Virol. 72:2560.
33. Zarling, J. M. 1986. T cell mediated immunity to herpes simplex viruses. In Human Herpesviruses. C. Lopez and B. Roizman, eds. Raven, New York, p. 103.
34. McMichael, A. J., and C. A. O'Callaghan. 1998. A new look at T cells. J. Exp. Med. 187:1367.
35. Newman, M. J., J. Y. Wu, B. H. Gardner, K. J. Munroe, D. Leombrino, J. Recchia, C. R. Kensil, and R. T. Coughlin. 1992. Saponin adjuvant induction of ovalbumin specific CD8 cytotoxic T lymphocyte responses. J. Immunol. 148: 2357.
36. Stewart-Tull, D. E. S. 1997. The choice and mechanism of action of adjuvants. In Antigen Delivery Systems. B. Gander, H. P. Merkle, and G. Corradin, eds. Harwood, Amsterdam, The Netherlands, p. 57.
37. Singh, M., J. R. Carlson, M. Briones, M. Ugozzoli, J. Kazzaz, J. Barackman, G. Ott, and D. O'Hagan. 1998. A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. Vaccine 16: 1822.